Autoimmune hemolytic anemia

Autoimmune hemolytic anemia

Playing 1/12
  • Autoimmune Hemolytic Anemia

    YouTube 03:16
  • Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis

    YouTube 01:53
  • Cold and warm autoimmune hemolytic anemia

    YouTube 01:07
  • Cold Agglutinin Disease Animation - Mechanism of Disease

    YouTube 02:18
  • WAHA Warm Autoimmune Hemolytic Anemia AIHA

    YouTube 01:44
  • Hematology Test

    YouTube 01:15
  • Pneumonia, Animation

    YouTube 03:05
  • Examination of the Spleen - Clinical Examination

    YouTube 01:03
  • What does the liver do? - Emma Bryce

    YouTube 03:25
  • How I Discovered I was HIV Positive

    YouTube 03:00
  • Bilirubin Metabolism Simplified

    YouTube 02:35
  • What is Hepatitis C and Why Should You Care?

    YouTube 02:29

Autoimmune hemolytic anemia occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. The lifetime of the RBCs is reduced from the normal 100–120 days to just a few days in serious cases. The intracellular components of the RBCs are released into the circulating blood and into tissues, leading to some of the characteristic symptoms of this condition. The antibodies are usually directed against high-incidence antigens, therefore they also commonly act on allogenic RBCs. AIHA is a relatively rare condition, affecting one to three people per 100,000 per year.

Discover in context

This site is not available in the landscape mode.
Please rotate your phone or install our app.